Regencell Bioscience ( ($RGC) ) has issued an announcement.
On May 8, 2026, Regencell Bioscience filed a Form 6-K with the U.S. Securities and Exchange Commission, incorporating this report into its existing shelf registration and prospectus. The filing provided investors with updated financial disclosure for the six months ended December 31, 2025, including interim results and XBRL-formatted data, underscoring the company’s intent to maintain access to U.S. capital markets.
The company reported unaudited condensed consolidated interim financial statements showing total assets of about $3.0 million and shareholders’ equity of $1.2 million as of December 31, 2025, down sharply from June 30, 2025. For the same six-month period, Regencell recorded a net loss of approximately $5.3 million, driven by a 170% year-on-year rise in operating expenses to $5.3 million, primarily from higher general and administrative costs, signaling increased cash burn and pressure on its balance sheet.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is a Hong Kong-based bioscience company listed on Nasdaq that focuses on developing treatments and therapies, with operations reported under U.S. GAAP and financial statements presented in U.S. dollars. The company operates with a functional currency of the Hong Kong dollar and targets international capital markets through its foreign private issuer status.
Average Trading Volume: 139,109
Technical Sentiment Signal: Buy
Current Market Cap: $15.56B
Find detailed analytics on RGC stock on TipRanks’ Stock Analysis page.
